ISOX-INACT

ISOX-INACT

Biochem/physiol Actions

CBP BRD (CREB binding protein bromodomain) inhibition serves as an effective therapeutic target for Parkinson’;s disease. The inhibition is followed by negative regulation of a number of macrophage inflammatory genes. It also downregulates G-protein signaling 4 mRNA.

ISOX-INACT is an inactive control probe for the highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) PF-CBP1.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Gene Regulation research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573766 ISOX-INACT white to beige 100 FTOHXUPHICJSCR-UHFFFAOYSA-N 1S/C29H36N4O3/c1-19-18-25-29(20(2)27(19)28-21(3)31-36-22(28)4)30-26(11-8-23-6-9-24(34-5)10-7-23)33(25)13-12-32-14-16-35-17-15-32/h6-7,9-10,18H,8,11-17H2,1-5H3
£408.11 (exc VAT) per 25MG
-
+
3573767 ISOX-INACT white to beige 100 FTOHXUPHICJSCR-UHFFFAOYSA-N 1S/C29H36N4O3/c1-19-18-25-29(20(2)27(19)28-21(3)31-36-22(28)4)30-26(11-8-23-6-9-24(34-5)10-7-23)33(25)13-12-32-14-16-35-17-15-32/h6-7,9-10,18H,8,11-17H2,1-5H3
£114.34 (exc VAT) per 5MG
-
+